tiprankstipranks
Trending News
More News >
Cann Group Ltd. (AU:CAN)
ASX:CAN
Advertisement

Cann Group (CAN) AI Stock Analysis

Compare
16 Followers

Top Page

AU:CAN

Cann Group

(Sydney:CAN)

Select Model
Select Model
Select Model
Neutral 45 (OpenAI - 4o)
Rating:45Neutral
Price Target:
AU$0.00
▼(-100.00% Downside)
Cann Group's overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues, substantial losses, and negative equity. While technical analysis shows some short-term bullish signals, the valuation remains unattractive due to a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events further limits positive influences on the score.

Cann Group (CAN) vs. iShares MSCI Australia ETF (EWA)

Cann Group Business Overview & Revenue Model

Company DescriptionCann Group Limited engages in the breeding, cultivation, production, manufacturing, clinical evaluation, and supplying medicinal cannabis for sale and use within Australia and for overseas export markets. It licenses to undertake research and to cultivate cannabis for human medicinal and research purposes. The company was founded in 2014 and is based in Port Melbourne, Australia.
How the Company Makes MoneyCann Group Limited generates revenue primarily through the sale of medicinal cannabis products. The company cultivates cannabis plants and processes them into various forms suitable for therapeutic use, including oils and dried flowers. Revenue streams include domestic sales within Australia and exports to international markets where medicinal cannabis is legally accepted. Cann Group also benefits from research partnerships and licensing agreements that leverage its expertise in cannabis cultivation and production.

Cann Group Financial Statement Overview

Summary
Cann Group Ltd. has shown revenue growth but faces significant profitability and leverage challenges. The high debt-to-equity ratio and continuous losses indicate a need for operational and financial restructuring.
Income Statement
25
Negative
Cann Group Ltd. shows a consistent increase in revenue over the years, with a notable jump from 2022 to 2023, reflecting a revenue growth of 11.58%. However, the company is struggling with negative margins, including a gross profit margin of 20.78% and a significant net loss margin of -333.33% in 2024. The EBIT and EBITDA margins are also negative, indicating operational inefficiencies.
Balance Sheet
20
Very Negative
The balance sheet reveals a high debt-to-equity ratio of 5.21, indicating heavy reliance on debt financing, which can be risky. The equity ratio has decreased significantly over the years to 15.01% in 2024. Additionally, negative return on equity highlights the lack of profitability from shareholders' investments.
Cash Flow
30
Negative
Cash flow analysis shows a negative free cash flow, though it improved from -25.94 million in 2023 to -17.69 million in 2024. The operating cash flow to net income ratio is negative, reflecting challenges in converting revenue to cash. The financing cash flow remains positive, suggesting dependency on external financing.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue15.51M13.25M15.37M13.78M6.41M4.29M
Gross Profit-3.96M5.15M-21.75M20.63M11.24M4.25M
EBITDA-9.43M-8.94M-35.54M-24.63M-19.79M-22.55M
Net Income-47.60M-22.34M-51.24M-33.79M-26.47M-25.10M
Balance Sheet
Total Assets84.97M78.79M92.77M129.47M139.66M101.79M
Cash, Cash Equivalents and Short-Term Investments60.00K10.00K1.64M765.00K1.91M3.10M
Total Debt72.36M75.84M72.47M60.97M47.16M680.00K
Total Liabilities78.65M81.56M78.85M70.20M54.76M9.92M
Stockholders Equity6.32M-2.77M13.92M59.26M84.90M91.87M
Cash Flow
Free Cash Flow-13.90M-9.80M-17.69M-25.94M-65.60M-37.10M
Operating Cash Flow-13.65M-9.64M-15.19M-22.84M-20.43M-20.83M
Investing Cash Flow3.43M-157.00K1.18M-28.00K-45.16M-17.08M
Financing Cash Flow8.53M8.17M14.77M21.71M64.41M39.47M

Cann Group Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.01
Price Trends
50DMA
0.01
Positive
100DMA
0.01
Positive
200DMA
0.02
Negative
Market Momentum
MACD
<0.01
Positive
RSI
51.88
Neutral
STOCH
13.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CAN, the sentiment is Neutral. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 51.88 is Neutral, neither overbought nor oversold. The STOCH value of 13.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:CAN.

Cann Group Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
AU$43.08M12.047.64%3.08%0.13%-12.90%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
45
Neutral
$9.85M-401.36%-26.49%61.72%
41
Neutral
AU$20.04M-218.38%-47.30%82.53%
39
Underperform
AU$4.26M16.0069.59%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:CAN
Cann Group
0.01
-0.04
-73.58%
AU:EPN
Epsilon Healthcare Limited
0.02
0.00
0.00%
AU:LGP
Little Green Pharma Ltd.
0.14
0.06
75.00%
AU:BOD
Bod Australia Ltd
0.02
0.00
0.00%
AU:AGH
Althea Group Holdings Ltd.
0.02
-0.02
-50.00%
AU:VIT
Cronos Australia Ltd.
0.07
-0.02
-22.22%

Cann Group Corporate Events

Cann Group Reports Record Production and Sales Growth in Q4 2025
Jul 31, 2025

Cann Group Limited reported a record production of 2.05 tonnes of dried flower in Q4 2025, marking a 41% increase from the previous quarter and contributing to a full-year production of 5.94 tonnes. The company achieved an 8% increase in sales, reaching $2.51 million for the quarter, and improved its net operating cash outflows by 13% compared to the prior quarter. With new debt and equity funding secured, Cann Group is poised for continued growth, focusing on restructuring its balance sheet and maximizing revenue as it enters FY2026.

Cann Group Limited Announces Quotation of New Securities on ASX
Jul 8, 2025

Cann Group Limited has announced the quotation of 15,130,872 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of July 8, 2025. This move is part of the company’s strategic efforts to enhance its market presence and provide liquidity to its stakeholders, potentially strengthening its position in the medicinal cannabis sector.

Cann Group Appoints CEO to Permanent Position
Jul 1, 2025

Cann Group Limited has announced the conversion of Ms. Jenni Pilcher’s role as CEO & Managing Director from a fixed-term contract to a permanent position. This decision reflects the board’s satisfaction with her performance and aligns with the company’s best interests, ensuring stability in its leadership as it continues to focus on its strategic objectives.

Cann Group Secures Additional R&D Funding Advance
Jun 16, 2025

Cann Group Limited has received a second advance of $315,552 from Radium Capital, providing early access to its expected R&D Tax Incentive for FY2025. This funding, along with a previous advance, totals $1,152,021 and will be repaid upon receipt of the R&D rebate or by 31 October 2025. This financial maneuver supports Cann Group’s ongoing R&D activities, potentially strengthening its position in the cannabis industry by ensuring continuous innovation and product development.

Cann Group Limited Announces Quotation of New Securities
Jun 13, 2025

Cann Group Limited has announced the quotation of 13,970,244 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of June 13, 2025. This move reflects the company’s efforts to enhance its capital structure and potentially expand its market presence, which could have significant implications for its stakeholders and position within the medicinal cannabis industry.

Cann Group Limited Announces Cessation of Securities
Jun 6, 2025

Cann Group Limited announced the cessation of several securities due to the lapse of conditional rights, as the conditions for these securities were not met or became incapable of being satisfied. This cessation involves a total of 3,795,886 securities, impacting the company’s issued capital and potentially affecting stakeholder interests.

Cann Group Issues New Unquoted Options to Bolster Growth
Jun 4, 2025

Cann Group Limited announced the issuance of 49,376,573 unquoted options, set to expire on June 4, 2027, with an exercise price of $0.03. This issuance is part of a previously announced transaction, indicating strategic financial maneuvers to support the company’s growth and operational objectives. The move could potentially impact the company’s market positioning by enhancing its financial flexibility and offering stakeholders an opportunity for future engagement.

Cann Group Resolves Legal Dispute with Rua Biosciences, Establishes New Commercial Ties
Jun 3, 2025

Cann Group Limited has resolved its legal dispute with Rua Biosciences Limited by entering into a confidential deed of settlement and release, which includes mutual release from claims and two commercial agreements for Cann to supply medicinal cannabis products to Rua for distribution in Australia and New Zealand. This settlement not only resolves the dispute but also establishes a new commercial relationship between the two companies, potentially impacting their operations and market positioning positively.

Cann Group Issues New Unquoted Equity Securities
Jun 2, 2025

Cann Group Limited has announced the issuance of 7,924,832 unquoted equity securities in the form of options set to expire on June 2, 2027, with an exercise price of $0.0508. This move is part of previously announced transactions and is not intended for quotation on the ASX, potentially impacting the company’s financial strategy and stakeholder interests by expanding its equity base.

Cann Group Issues New Unquoted Equity Securities
Jun 2, 2025

Cann Group Limited has announced the issuance of 1,746,147 unquoted equity securities in the form of options set to expire on June 2, 2027, with an exercise price of $0.0573. This issuance is part of a previously announced transaction and is not intended to be quoted on the ASX, potentially impacting the company’s financial strategy and stakeholder interests by expanding its equity base.

Cann Group Announces Successful Resolutions at General Meeting
May 30, 2025

Cann Group Limited announced the results of its General Meeting, where all resolutions were passed following a poll vote. The meeting included significant decisions such as the election of a director and the ratification of share and option issuances, which are expected to impact the company’s strategic direction and stakeholder interests positively.

Cann Group Limited CEO to Present Strategic Updates at EGM
May 30, 2025

Cann Group Limited announced a presentation by CEO Jenni Pilcher at their Extraordinary General Meeting, focusing on the company’s operations, sales, funding, and strategy. This announcement highlights the company’s ongoing efforts to strengthen its market position and operational capabilities, potentially impacting its stakeholders positively.

Cann Group Limited Announces Quotation of New Securities on ASX
May 20, 2025

Cann Group Limited has announced the application for quotation of 11,607,322 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of May 20, 2025. This move is part of the company’s strategic efforts to bolster its financial position and enhance its market presence, potentially impacting its operations and offering new opportunities for stakeholders.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 07, 2025